Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Zymeworks Inc.
  6. Company
    ZYME   US98985Y1082

ZYMEWORKS INC.

(ZYME)
  Report
Delayed Nasdaq  -  04:00:00 2023-02-06 pm EST
9.820 USD   +3.59%
01/25Zymeworks Announces Participation in Upcoming Investor Conferences
BU
01/20Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma
AQ
01/20SVB Securities Raises Price Target on Zymeworks to $10 From $8, Maintains Market Perform Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Business Summary
Logo Zymeworks Inc.
Zymeworks Inc. is a clinical-stage biopharmaceutical company that is engaged in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer. Its lead product candidate is zanidatamab, a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its product candidate ZW49, combines the design of zanidatamab with its ZymeLink ADC platform, comprised of its cytotoxin and cleavable linker. The Company operates through a number of platforms, including Azymetric, ZymeLink, EFECT and ProTECT. Its Azymetric is a bispecific platform that enables therapeutic antibodies to simultaneously bind multiple distinct locations on a target or to multiple targets. The CompanyÔÇÖs ZymeLink is an antibody-drug conjugate (ADC) platform comprised of cytotoxins and the linker technology used to couple these cytotoxins to tumor-targeting antibodies or proteins.

Number of employees : 458 people.
Sales per Business
20202021Delta
Next-generation Multifunctional Biotherapeutics38.95100%26.68100% -31.5%
USD in Million
Sales per region
20202021Delta
Canada38.95100%26.68100% -31.5%
USD in Million
Managers
Name Title Age Since
Kenneth Harry Galbraith Chairman & Chief Executive Officer 59 2022
Neil A. Klompas Chief Financial Officer 50 2007
Christopher Astle, Dr. Chief Financial Officer & Senior Vice President 42 2022
Paul A. Moore, Dr. Chief Scientific Officer - 2022
Daniel Dex Secretary & Vice President-Legal - -
Members of the board
Name Title Age Since
Kenneth Harry Galbraith Chairman & Chief Executive Officer 59 2022
Lota Zoth Lead Independent Director 62 -
Troy Cox Director 57 -
Kenneth J. Hillan, Dr. Director 61 -
Susan Mahony, Dr. Director 57 -
Kelvin M. Neu, Dr. Director 48 -
Hollings Chase Renton Director 75 -
Natalie R. Sacks, Dr. Director 57 -
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 62,996,314 54,487,170 86.5% 0 0.0% 86.5%
Shareholders
NameEquities%
Ecor1 Capital LLC 9,887,473 15.7%
Redmile Group LLC 6,075,918 9.64%
BVF Partners LP 5,870,000 9.32%
Armistice Capital LLC 5,785,000 9.18%
Eventide Asset Management LLC 5,380,200 8.54%
Morgan Stanley & Co. LLC 5,251,880 8.34%
Perceptive Advisors LLC 4,400,099 6.98%
Fidelity Investments Canada ULC 3,376,211 5.36%
Camber Capital Management LP 2,865,000 4.55%
Daniel Cookson 2,786,936 4.42%
Brand Portfolio
In partnership withAllbrands.markets
More brands of Zymeworks Inc.